8h às 08h20 - Artigo 1: Larkin, J. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate-067) - N Engl J Med 2019; 381:1535

 Dr. Rodrigo Munhoz (HSL).

8h20 às 08h40 - Artigo 2: Makker, V. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial – Lancet Oncol. 2019 May;20(5):711  

Dra. Michelle Samora (H9J).

8h40 às 09h - Artigo 3:  Schmid, P. KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) – ESMO Annual Meeting 2019, LBA8_PR

Dr. Felipe Ades (HAOC)

9h às 09h20 - Artigo 4: Rini, B. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma – N Engl J Med 2019, 380:1116

 Dr. Ariel Kann (HAOC)

9h20 às 09h40- Artigo 5: Hellmann, M. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer - N Engl J Med 2018 sept 28; Epub ahead of print.

Dr. Marcos André (HAOC) 

9h40 às 10h - Artigo 6: Paz-Ares, L. Pembrolizumab plus chemotherapy for squamous NSCLC (KN-407) – N Engl J Med 2018 nov 22; 379:2040 –

Dra. Cláudia Sette (ABC)

10h 10h40 - Intervalo:

10h40 às 11h- Artigo 7: Antonia, S. Overall Survival with Durvalumab after chemoradiotherapy in stage III NSCLC – N Engl J Med 2018 dec 13; 379:2342

 Dr. Cheng Tzu (HAOC).

11h às 11h20 - Artigo 8: Kato, K. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3) – Lancet Oncology 2019 Sep 27. pii: S1470-2045(19)30626

 Dr. Diogo Bugano (HIAE)

11h20 às 11h40 - Artigo 9: Horn, L. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer – N Engl J Med 2018 dec 6; 379:2220 – À confirmar

11h40 às 12h- Artigo 10: Jin Y. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC - J Thorac Oncol 2019 Aug;14(8):1378 –

Dr. Dan Waitzberg

Patrocínio